Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.
Anne MontfortThomas FilleronMathieu VirazelsCarine DufauJean MilhèsCécile PagèsPascale OlivierMaha AyyoubMuriel MounierAmélie LusqueStéphanie BrayerJean-Pierre DelordNathalie Andrieu-AbadieThierry LevadeCéline ColaciosBruno SéguiNicolas MeyerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our results show that both combinations are safe in human and provide clinical and biological activities. The high response rate in the certolizumab-treated patient cohort deserves further investigations.